Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) EBT (2016 - 2025)

CorMedix has reported EBT over the past 16 years, most recently at $56.4 million for Q4 2025.

  • Quarterly results put EBT at $56.4 million for Q4 2025, up 73.52% from a year ago — trailing twelve months through Dec 2025 was $150.0 million (up 58021.24% YoY), and the annual figure for FY2025 was $150.0 million, up 58021.24%.
  • EBT reached $56.4 million in Q4 2025 per CRMD's latest filing, up from $52.6 million in the prior quarter.
  • Across five years, EBT topped out at $56.4 million in Q4 2025 and bottomed at -$15.9 million in Q1 2024.
  • Median EBT over the past 5 years was -$7.5 million (2021), compared with a mean of $2.2 million.
  • The largest annual shift saw EBT plummeted 74.94% in 2023 before it soared 1993.4% in 2025.
  • Over 5 years, EBT stood at -$7.8 million in 2021, then fell by 5.36% to -$8.2 million in 2022, then tumbled by 74.94% to -$14.4 million in 2023, then surged by 326.52% to $32.5 million in 2024, then skyrocketed by 73.52% to $56.4 million in 2025.
  • Business Quant data shows EBT for CRMD at $56.4 million in Q4 2025, $52.6 million in Q3 2025, and $20.3 million in Q2 2025.